open access

Vol 14, No 5 (2018)
Guidelines / Expert consensus
Published online: 2019-02-15
Get Citation

Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018

Andrzej Marszałek, Maciej Krzakowski
DOI: 10.5603/OCP.2018.0034
·
Oncol Clin Pract 2018;14(5):272-277.

open access

Vol 14, No 5 (2018)
STANOWISKO EKSPERTÓW (EXPERTS' OPINION)
Published online: 2019-02-15

Abstract

New recommendations for HER2 status (receptor or gene) testing in breast cancer were published following
long-term analysis of clinical effectiveness of molecularly targeted treatment based on predictive factor of
HER2 status. The new protocols were developed to eliminate equivocal cases, and the new procedure leads to
final statement as HER2 positive or HER2 negative. Current testing algorythms are presented.

Abstract

New recommendations for HER2 status (receptor or gene) testing in breast cancer were published following
long-term analysis of clinical effectiveness of molecularly targeted treatment based on predictive factor of
HER2 status. The new protocols were developed to eliminate equivocal cases, and the new procedure leads to
final statement as HER2 positive or HER2 negative. Current testing algorythms are presented.

Get Citation

Keywords

HER2; breast cancer; recommendations

About this article
Title

Recommendations for testing of predictive marker HER2 in patients with invasive breast cancer. Recommendations in accordance with American Society of Clinical Oncology (ASCO) guidelines from 30th May 2018

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 5 (2018)

Article type

Guidelines / Expert consensus

Pages

272-277

Published online

2019-02-15

DOI

10.5603/OCP.2018.0034

Bibliographic record

Oncol Clin Pract 2018;14(5):272-277.

Keywords

HER2
breast cancer
recommendations

Authors

Andrzej Marszałek
Maciej Krzakowski

References (5)
  1. www.pathologyoutlines.com (26.09.2018).
  2. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. JCO. 2018; 36: 1–20.
  3. Olszewski W, Chmielik E, Kordek R. Sutek. Pol J Pathol. 2015; 66(4; Suppl 1): 30–35.
  4. Yildiz-Aktas IZ, Dabbs DJ, Cooper KL, et al. The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am J Clin Pathol. 2012; 137(5): 691–698.
  5. Hanna W, Barnes P, Berendt R, et al. Testing for HER2 in breast cancer: current pathology challenges faced in Canada. Curr Oncol. 2012; 19(6): 315–323.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl